Clinical Spectrum and Molecular Characteristics of Inherited Ocular Diseases in a Cohort of Pediatric Patients With Infantile Nystagmus Syndrome

Abstract

Purpose

Infantile nystagmus syndrome (INS), the most prevalent form of nystagmus in children, often indicates underlying ocular and neurological conditions. Genetic assessment plays a crucial role in clinical management, genetic counseling, and access to emerging gene-based therapies. This study aims to characterize the clinical and genetic landscape of inherited ocular diseases (IODs) in children with INS.

Methods

We retrospectively analyzed clinical and genetic data from 205 unrelated pediatric patients with INS enrolled in an IRB-approved nystagmus registry (2010–2024). All underwent next-generation sequencing (NGS) with targeted gene panels to detect pathogenic variants.

Results

The cohort comprised 117 males and 88 females (mean [SD] age, 8.85 [10.37] years). The most common INS-associated IODs included albinism (32%), Leber congenital amaurosis (LCA) (14%), and achromatopsia (14%). Genetic testing achieved a definitive diagnosis in 85 of 205 patients, yielding a molecular diagnostic rate of 41.5%. A total of 83 pathogenic and likely pathogenic variants were identified across 30 genes. The seven most frequently disease-causing genes—TYR, CNGB3, RPGR, GPR143, ABCA4, OCA2 and FRMD7—accounted for 65% of the genetically solved cases. Additionally, eight genes associated with LCA (AIPL1, CABP4, GUCY2D, IMPDH1, NMNAT1, RDH12, PRPH2, and RPGRIP1) contributed to 15% of these cases.

Conclusions

This study underscores the utility of NGS in diagnosing INS-associated IODs, providing essential insights for targeted interventions and identifying patients as candidates potentially eligible for ongoing gene-based therapy clinical trials.

Infantile nystagmus syndrome (INS) is a unique ocular motor disorder characterized by involuntary, rhythmic oscillation of the eyes, typically manifesting within the first six months of life. It is closely associated with congenital or early-onset defects in the visual sensory system.^1,2 INS is the most common form of nystagmus in infancy and childhood, with an incidence of approximately 1.7 per 1000 live births, and often serves as an indicator of underlying ocular, neurological, or systemic conditions.^3,4 Although INS may occur as an isolated, idiopathic, or inherited disorder, it is often associated with other ocular disorders such as albinism, aniridia, achromatopsia, congenital retinal dystrophies, early-onset retinal degeneration, Joubert syndrome, Bardet Biedl syndrome, congenital cataracts, optic nerve hypoplasia, corneal dystrophies, and many others.⁵ Neurological syndromes and neurologic diseases, including brain tumors, spinocerebellar ataxia, glioma, and structural brain malformations, are also known associations.⁶

Regardless of its etiology, INS invariably arises from a disturbance in ocular motor calibration during a developmental “sensitive period” occurring between one and five months of age, leading to a runaway high gain instability of the smooth pursuit system.⁷ Differentiating INS from other neurologically nonsignificant and significant forms of nystagmus often requires detailed eye movement recordings to characterize waveform patterns.⁸ A comprehensive evaluation, including advanced ophthalmological, neurological, and imaging modalities—such as optical coherence tomography, fundus autofluorescence, electroretinograms and visual evoked potentials, and brain magnetic resonance imaging—is often used.⁹ Despite the availability of these diagnostic tools, their utility in pediatric patients may be limited because of poor cooperation or the severity of the nystagmus.

Evaluating INS in infants and children presents significant challenges, given its association with both idiopathic disorders and early-onset defects in the visual sensory system.⁹ Approximately 90% of INS cases are associated with visual sensory disorders, either anatomical or functional,¹⁰ many of which are inherited ocular disorders (IODs).¹¹ These disorders exhibit significant clinical and genetic heterogeneity, often leading to severe visual impairment in childhood.¹² The diverse genetic landscape of these disorders complicates their identification, as over 150 genes have been implicated in IODs among children with INS, leading to considerable phenotypic overlap.¹³ These genes encompass a wide array of mutations and are implicated in disorders with distinct inheritance patterns, including autosomal recessive, and autosomal dominant, X-linked, and mitochondrial mode.¹⁴ Advances in next-generation sequencing (NGS) have improved diagnostic capabilities in these patients.¹⁵ However, comprehensive genetic analyses of IODs in children with INS remain limited.

Recent technological advancements in genotyping and sequencing have significantly enhanced our understanding of the mechanisms of IODs frequently observed in INS, offering potential refinements in diagnostic algorithms. Phenotype-driven NGS panels have shown high diagnostic accuracy, resolving 35% to 80% of cases in small cohorts of INS patients.^16–19 Despite the progress, genetic data for the broader pediatric population with INS remains limited. Establishing a genetic diagnosis for INS patients is crucial for providing genetic counseling and assessing the risk of recurrence in family members of affected patients, and it is increasingly important for eligibility in emerging gene-based therapies.²⁰

This study aimed to evaluate the genetic spectrum of INS-associated IODs in a cohort of 205 pediatric patients. Through a cross-sectional analysis, we examined the gene distribution, diagnostic yield, and the underlying molecular etiology. Gaining insights into the genetic landscape of IODs in children with INS will enable the early diagnosis and a crucial window for effective intervention and facilitate patients access to emerging gene-based therapies and ongoing clinical trials.

Methods

Patient Selection and Ethical Considerations

This prospective study included data from 4232 patients diagnosed with nystagmus at Akron Children's Vision Center between January 1, 2010, and March 31, 2024. All data were obtained from a Health Insurance Portability and Accountability Act–compliant, institutional review board–approved database at Akron Children's Hospital. This secure digital database includes comprehensive clinical, demographic, and familial information, such as family pedigree, age at symptom onset, systemic findings, and geographic origin. Eligible patients had a clinical diagnosis of infantile nystagmus and had consented to or previously completed genetic testing.

Genetic Testing and Data Analysis

Genetic analysis used targeted NGS panels or whole exome sequencing. Testing was conducted by accredited commercial laboratories (Blueprint Genetics, Invitae, GeneDx, and Prevention Genetics), using disease-specific NGS and virtual panels for nystagmus and inherited retinal diseases. A custom bioinformatic pipeline processed sequencing data, aligning reads to the NCBI RefSeq transcripts and GRCh37/hg19 reference genome using the Burrow-Wheeler Aligner algorithm. Post-alignment steps included duplicate read removal, local realignment around indels, base quality score recalibration, and variant calling using the Genome Analysis Toolkit. Variants classified as pathogenic or likely pathogenic were further evaluated.

Variant Classification

Variants were classified following American College of Medical Genetics and Genomics and Association for Molecular Pathology guideline.^21,22 Patients were categorized into three groups: (1) Probable Molecular Diagnosis: those with pathogenic/likely pathogenic variants consistent with phenotype and inheritance patterns, requiring one likely pathogenic or pathogenic variant for autosomal dominant and two pathogenic or likely pathogenic variants for autosomal recessive conditions; (2) Possible Molecular Diagnosis: those with two heterozygous variants without segregation analysis or one pathogenic/likely pathogenic variant in a recessive gene matching the clinical phenotype; (3) Unsolved: those with no pathogenic or likely pathogenic variants, or only variants of uncertain significance (VUS).

Statistical Analysis

Data were analyzed using IBM SPSS Statistics for Windows, version 23.0 (IBM, Armonk, NY, USA). Descriptive statistics included numbers, percentages, mean ± standard deviation or median ± interquartile range, as appropriate. Paired continuous variables were compared using the Wilcoxon signed-rank test, with statistical significance set at P < 0.05 and 95% confidence intervals.

Results

Demographic and Clinical Characteristics of the Pediatric INS Cohort

The study included data from 4232 patients with INS enrolled in the nystagmus registry at Akron Children's Vision Center between 2010–2024, with a focus on 205 unrelated pediatric patients who underwent genetic testing. This cohort included 117 males (57%) and 88 females (43%), adjusting to a nearly equal sex ratio (49.3% males, 50.7% females) when excluding X-linked cases. Ages at genetic testing ranged from 0.3 to 40 years, with a mean of 8.54 ± 7.91 years. Clinical examination revealed varied degrees of visual acuity reduction (Table).

Table.

Demographic and Clinical Characteristics of IOD Patients With INS

Clinical Feature	Genetically Tested Cases (N = 205)	Genetically Solved Cases (N = 85)
Sex
Male	117 (57%)	49 (57%)
Female	88 (43%)	36 (43%)
Age (y) at testing
<0.6	12 (5.9)	2 (2.4)
0.6–1.0	14 (6.8)	6 (7.1)
1.0–2.0	17 (8.3)	11 (12.9)
2.0–5.0	41 (20.1)	16 (18.8)
5.0–10	63 (30.7)	25 (29.4)
10–20	49 (23.9)	19 (22.4)
>20	9 (4.4)	6 (7.1)
Family history
Positive	80 (39.1)	48 (56.5)
Negative	125 (59.9)	37 (43.5)
Best-corrected visual acuity
OD LogMAR ≤0.3	38 (18.5)	13 (15.3)
≥0.3–≤0.6	57 (27.8)	25 (29.4)
≥0.6	42 (20.5)	28 (32.9)
Fix and follow	68 (33.2)	19 (22.3)
OS LogMAR ≤0.3	34 (16.6)	9 (10.6)
≥0.3–≤0.6	61 (29.8)	30 (35.3)
≥0.6	42 (20.5)	27 (31.8)
Fix and follow	68 (33.2)	19 (22.3)
Nystagmus
With associated finding	186 (90.7)	82 (96.4)
Without associated finding	19 (9.3)	3 (3.6)

Among those with a confirmed genetic diagnosis (or molecular diagnosis) (n = 85), 96% displayed associated clinical findings, with oculocutaneous albinism type 1 and type 2 (25%), achromatopsia (14%), Leber congenital amaurosis (LCA, 14%), X-linked retinitis pigmentosa (7%), as the most frequent phenotypes (Fig. 1).

Figure 1.

Clinical phenotypic spectrum in the genetically solved cohort with INS and INS-associated ocular conditions.

Variants Spectrum and Molecular Diagnostic Yield

A total of 205 patients who underwent genetic testing at the time of this study were analyzed. Across 175 unrelated patients (85.4%) with detected variants, a total of 406 variants in phenotype-related genes were identified, including 136 pathogenic variants, 59 likely pathogenic variants, 18 risk alleles, and 193 variants of uncertain significance (VUS) (Supplementary Table S1). The detected variants spanned a broad range of types, including 306 missense (75%), 36 frameshift (9%), 28 splice-site (7%), 17 stop-gain (4%), seven large deletions (2%), and six in-frame indels or copy number losses (1.5%) (Fig. 2, insert).

Figure 2.

Genetic findings and molecular diagnostic rate of targeted NGS in patient cohort with INS. Variants were detected in 85% of the patients. Based on variant classification, the pathogenic mutations were determined to cause diseases in 42% of the patients. The percentages are calculated over the total number of patients who underwent genetic testing. Insert: Pie chart showing the spectrum of variant types among all detected genes.

A probable molecular diagnosis was established in 85 patients, yielding a diagnostic rate of 41.5% (95% CI, 36.2%–46.7%), whereas 25.3% (n = 52) had only one pathogenic or likely pathogenic variant in a recessive gene, indicating possible carrier status. Unsolved cases included 18.5% (n = 38) with VUS. Family history was reported in 56.5% of probable, 36.5% of possible, and 26.3% of VUS cases (Fig. 2, Supplementary Table S1).

Genetic Characteristics and Causative Gene Prevalence

Our analysis identified 83 distinct causative variants across 30 genes in genetically solved cases. Single-nucleotide variants were the most frequent variant type, representing 93% of cases. Of the pathogenic alleles identified, 60% involved single-nucleotide substitutions leading to missense mutations. Protein truncating variants accounted for 33% of pathogenic alleles, encompassing nonsense (7%), frameshift (20%), and canonical splice site variants (6%). In contrast, small insertions/deletions (in/dels) and larger structural variants were identified in approximately 7% of mutated alleles (Fig. 3A and Supplementary Table S1)

Figure 3.

Types of gene variants and prevalence of disease-associated causative genes identified in the genetically solved INS cohort. (A) Pie chart showing the distribution of all the gene variants underlying INS or its associated conditions according to their types. (B) Prevalence of disease-associated genes harboring causative variants in patients with INS.

The most frequently mutated genes included TYR (n = 17 [20%]) and OCA2 (n = 4 [4.7%]) for oculocutaneous albinism, CNGB3 (n = 8 [9.4%]) for achromatopsia, GPR143 (n = 6 [7%]) for X-linked ocular albinism, RPGR (n = 6 [7%]) for X-linked retinitis pigmentosa, ABCA4 (n = 5 [5.9%]) for Stargardt disease, and FRMD7 (n = 3 [3.5%]) for idiopathic INS. Eight LCA-associated genes (AIPL1, CABP4, GUCY2D, IMPDH1, NMNAT1, RDH12, PRPH2 and RPGRIP1) accounted for 15% of genetically diagnosed cases, with other genes having lower prevalence (Fig. 3B).

Gene-Specific Variants

TYR (Tyrosinase, MIM no. 606933) was the most prevalent causative gene, identified in 17 cases. In TYR, 19 distinct pathogenic alleles were detected, with missense variants comprising 72.2% of disease-causing alleles, followed by protein truncating variants (22.2%) and splice site variants (5.6%). Among the frequent variants, c.1205G>A, p.(Arg402Gln), and c.575C>A, p.(Ser192Tyr) was predominant in patients with oculocutaneous albinism type 1 (OCA1), manifesting as hypomorphic albinism when co-occurring with other pathogenic TYR variants. Other notable variants included c.230G>A, p.(Arg77Gln) and c.1118C>A, p.(Thr373Lys) (Fig. 4A).

Figure 4.

Most frequent variants identified in TYR- and CNGA3-/CNGB3-associated probands in genetically solved cohort. (A) Histogram showing the most frequent TYR variants. (B) Histogram of occurrence of the most recurrent CNGA3, CNGB3 and ATF6 variants.

Pathogenic variants in CNGB3 (cyclic nucleotide gated channel subunit beta 3, MIM no. 605080) were the second most frequent in the cohort, primarily associated with achromatopsia. In 12 patients, pathogenic variants were identified in three causative genes of achromatopsia, CNGA3 in two patients, CNGB3 in eight patients and ATF6 in two patients. As shown in Figure 4B, 62.5% (n = 5) of CNGB3 variants was homozygous for the c.1148delC variant, a well-known frameshift mutation, whereas compound heterozygous states were observed in three patients with combinations of other splice site and frameshift variants.

Mutations in RPGR (Retinitis pigmentosa GTPase regulator, MIM no. 312610), associated with X-linked retinitis pigmentosa, were the third most prevalent. Among the six patients, four were males with hemizygous variants including one nonsense mutation, one novel deletion, and a frameshift variant. Interestingly, two female carriers exhibited milder retinal phenotypes, despite carrying pathogenic RPGR variants (Fig. 5A, Supplementary Table S1).

Figure 5.

Most frequently found variants in the genetically solved cohort. (A) Bar graph showing the most frequently found variants in RPGR-associated probands. (B) Bar graph showing the most frequently found variants in ABCA4-associated probands. (C) Bar graph showing the most frequently found variants in GRP143-associated probands. (D) Bar graph showing the most frequently found variants in FRMD7-associated probands.

Ten distinct heterozygous variants in ABCA4 (ATP-binding cassette transport 4, MIM no. 601691) were identified across five unrelated patients. Missense mutations constituted 80% of the ABCA4 pathogenic alleles, whereas nonsense mutation, such as (c.4234C>T, p.Gln1412*), was identified in only one case (Fig. 5B). Being a recessive condition, the combination of heterozygous pathogenic variants in ABCA4 influences the phenotype severity.^23,24 No other disease variants that might explain nystagmus in these ABCA4 patients were present, and they did not have clinical features suspicious for the clinical diagnosis (e.g., relative hypopigmentation, the absence of clear central atrophy, etc.).

Hemizygous pathogenic variants in GPR143 (G-protein coupled receptor 143, MIM no. 300808), predominantly associated with ocular albinism type 1 (OA1), were identified in six patients. Variants included splice site, frameshift, and missense mutations, alongside a deletion affecting exons 1–8 in two related patients (Fig. 5C).

The pathogenic variants in FRMD7 (FERM domain-containing 7, MIM no. 300628) were identified in three unrelated patients. All FRMD7 variants were classified as likely pathogenic, comprising a hemizygous missense variant c.875T>C, p.(Leu292Pro), a heterozygous missense c.812 G>T, p.(Cys271Phe) and a hemizygous in-frame deletion variant c.31_33delGAT: p.(Asp11del), located in exon 1 of the FRMD7 gene (NM_194277.2) (Fig. 5D).

Inheritance Patterns

Among patients with a probable molecular diagnosis, pathogenic or likely pathogenic variants were found in autosomal genes (76.25%) and X-linked (23.75). The autosomal recessive (AR) inheritance was the predominant pattern among our patients with INS, constituting 58.75% (47/85) of genetically solved cases, with 46.25% (n  = 37) in compound heterozygous states and 12.5% (n = 10) homozygous. Autosomal dominant variants comprised 17.5% of solved cases and X-linked inheritance was found in 23.75% of cases (Fig. 6A).

Figure 6.

Inheritance patterns and distribution of mutated genes in the genetically solved probands. (A) Percentage of inheritance patterns based on molecular diagnosis. Data derived from 85 genetically solved probands out of 205 genetically tested patients. (B–D) The prevalence and relative contribution of causative genes implicated in autosomal recessive (B), autosomal dominant (C), and X-linked (D) forms.

The most frequently implicated disease-causing genes within the AR category were TYR (n = 17) and CNGB3 (n = 8), together accounting for nearly half of all AR cases. Following these, ABCA4 (n  =  5), OCA2 (n  =  4), and RDH12 (n  =  3) were also notable contributors (Fig. 6B). Autosomal dominant forms represented 17.5% of genetically solved cases, with mutations identified in genes such as ARID1B (n = 1), COL2A1 (n  =  4), COL11A1 (n  =  1), GUCY2D (n  =  1), IMPDH1 (n = 2), MFN2 (n = 1), MFRP (n = 1), PAX6 (n = 2), PRPH2 (n  =  1), and VCAN (n = 1) (Fig. 6C).

Furthermore, 23.75% of the solved cases exhibited hemizygosity for variants in genes linked to recessive X-linked phenotypes. Notably, the most recurrently implicated genes in this category were GRP143 (n  =  6), RPGR (n  =  6), FRMD7 (n = 3), OPN1LW (n = 2), CHM (n = 1), NYX (n  =  1), and RP2 (n  =  1) (Fig. 6D).

Discussion

This study aimed to delineate the molecular genetic spectrum of INS in a large pediatric cohort. From an initial pool of 4323 patients, comprehensive genetic analyses were performed on 205 individuals with INS or INS with associated conditions, using panel-based NGS to identify molecular diagnoses. This represents the largest genetically characterized INS cohort reported from a single vision center. Previous studies using NGS panels with 31 to 336 genes reported diagnostic yields ranging from 35% to 60%, depending on cohort size and gene panel composition.¹⁵ Diagnostic yields in these studies varied, with rates of 58.3% (28 of 48 patients)¹⁷, 60% (nine of 15 patients),¹⁶ 43.2% (35 of 81 patients)¹⁸ and 35% (13 of 37 patients).¹⁹ In our cohort, we achieved a definitive molecular diagnosis in 41.5% of patients and a possible molecular diagnosis in 24.6%, resulting in a combined diagnostic yield of 66.5% (Fig. 2). Although our yield is consistent with previously reported rates,^18,19 it is somewhat lower than those with higher rates,^16,17 which may reflect differences in gene panels, clinical phenotypes, or the presence of intronic and regulatory variants not captured by NGS.

Our study revealed a low rate of copy number variation (CNV) detection, with only 1% (six of 203) of cases showing CNVs. This low yield may reflect the limitations of NGS in detecting structural variants. Recent advances in whole-genome sequencing (WGS) and long-read sequencing technologies have improved the detection of such variants, suggesting that WGS could enhance diagnostic rates, especially in cases with negative NGS results.²⁵

Given the prevalence of nystagmus across various ocular and systemic diseases, accurate interpretation of genetic variants is critical for providing a precise diagnosis, optimizing clinical management, guiding family planning, and potentially enabling access to emerging gene-based therapies. In this study, we identified 77 previously unreported (likely) pathogenic variants, constituting 44.5% of the total (Supplementary Table S1). We also detected 138 variants of VUS, underscoring the challenge of reclassifying these variants with limited data. Family testing and functional studies may help clarify the clinical significance of these VUS.²⁶

Despite the diagnostic success, 58% of patients had either negative or inconclusive genetic findings. Negative results may stem from non-genetic clinical phenotypes or limitations of the gene panel used. In such cases, WGS or long read NGS may offer further insights, particularly for detecting variants in intronic or regulatory regions.²⁷ In cases with inconclusive results, especially those involving clinically relevant VUS with strong evidence supporting pathogenicity but insufficient data for definitive classification, functional studies or WGS could provide for further clarification. Additionally, segregation analysis through family testing could also aid in reclassifying VUS as either benign or pathogenic.^28,29

The phenotypic heterogeneity of INS-associated IODs reflects the diverse array of underlying genotypes. Clinically, INS-associated IODs can be classified into two main phenotypic categories: non-syndromic and syndromic. The majority are non-syndromic, primarily resulting from mutations in retina-specific genes, including those associated with achromatopsia, LCA, X-linked RP, blue cone monochromatism and congenital stationary night blindness. In contrast, syndromic INS-associated IODs, which involve multiple organs beyond the eyes, include conditions such as albinism (Fig. 1). A more detailed analysis of genotype-phenotype correlations of INS-associated IODs will be addressed in a future publication.

Among our solved cases, TYR mutations were the most frequently encountered, consistent with previous studies reporting TYR as the predominant gene associated with oculocutaneous albinism type 1 (OCA1).³⁰ We found that 65% of OCA1 patients harbored compound heterozygosity for a severe TYR variant and the hypomorphic TYR c.1205G>A (p.Arg402Gln) variant, which is insufficient to cause OCA1 in the heterozygous state alone.^31,32 This finding is consistent with previous studies and highlights the need to consider hypomorphic alleles in the diagnostic evaluation of OCA1.^33,34

Mutations in CNGB3 and CNGA3, commonly associated with achromatopsia, accounted for over 10% of genetically diagnosed cases in our cohort. The CNGB3 c.1148delC variant was particularly prevalent, consistent with previous studies identifying this variant as a major contributor to achromatopsia.³⁵

Variants in RPGR are associated with X-linked RP. It is well recognized that female carriers can show a disease phenotype of variable severity.³⁶ Two out of six patients in our genetically diagnosed cases were carrier females. Given the therapeutic potential for RPGR-related diseases, the identification of these mutations is particularly relevant as gene therapy trials for RPGR-associated RP are underway.

We identified three distinct mutations in FRMD7, a gene previously linked to idiopathic INS.^37–39 All three patients with FRMD7 mutations had a family history suggestive of X-linked inheritance. Two exhibited pendular nystagmus waveforms, while the third had unidirectional jerk nystagmus. One patient carrying a hemizygous in-frame deletion variant presented with relatively poor visual acuity and foveal hypoplasia on optical coherence tomography, features atypical for FRMD7-related INS. Mutations in FRMD7 represent the most common genetic cause of inherited nystagmus, followed by mutations in GPR143, the gene responsible for ocular albinism.⁴⁰ Our cohort's lower detection rate for FRMD7 variants compared to previous studies may reflect differences in population genetics or gene panel composition.^16,17,19,41 Additionally, GPR143 mutations have been reported in idiopathic INS cases, albeit without a distinctive clinical phenotype.^42,43

A significant finding in our study was the identification of 30 patients with actionable genotypes for gene-based therapies currently in clinical trials, including those targeting CNGA3, CNGB3 and RPGR. As gene therapies for these conditions advance, the demand for molecular diagnoses will increase, facilitating patient access to clinical trials and targeted treatments.

Despite the strengths of this study, several limitations should be noted. First, we used panel-based NGS without incorporating WGS, potentially missing structural or intronic variants. Second, the gene panel used evolved over time, with earlier patients tested on smaller panels, which may have affected diagnostic outcomes. Our low CNV detection rate further underscores the limitations of panel-based approaches, because WGS is more adept at identifying CNVs.⁴⁴ Finally, family testing was not always feasible, limiting our ability to perform segregation analysis for VUS.

In conclusion, we achieved a molecular diagnosis in 41.5% of pediatric INS cases using targeted NGS, with actionable findings for gene-based therapies in 35% of solved cases. The remaining unresolved cases highlight the need for more comprehensive genetic testing, including WGS, and further research into non-coding regions and CNVs. A multidisciplinary approach, integrating clinical, genetic, and imaging data, is essential for managing INS and its associated conditions. Our findings provide a foundation for future research aimed at improving the diagnostic and therapeutic strategies for INS and its related inherited ocular disorders.